MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

LVEF

  • Home
  • LVEF
Sex-Specific Outcomes of Beta-Blocker Therapy After Myocardial Infarction: Insights from the REBOOT Trial
Posted inCardiology news Specialties

Sex-Specific Outcomes of Beta-Blocker Therapy After Myocardial Infarction: Insights from the REBOOT Trial

Posted by By MedXY 09/02/2025
The REBOOT trial reveals a sex-specific differential effect of beta-blockers after MI, showing increased harm in women with preserved LVEF, challenging current guideline recommendations.
Read More
Decoding Cardiac Trajectories: Linking Systolic-Diastolic Function Patterns to Heart Failure Risk and Proteomics
Posted inCardiology news Specialties

Decoding Cardiac Trajectories: Linking Systolic-Diastolic Function Patterns to Heart Failure Risk and Proteomics

Posted by By MedXY 09/02/2025
This study integrates longitudinal systolic and diastolic cardiac function measures using Bayesian modeling to identify trajectories associated with distinct heart failure subtypes and proteomic signatures, enhancing risk prediction and therapeutic target discovery.
Read More
  • Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: Insights from the TEASE-1 Randomized Clinical Trial
  • Compartment-Specific Nodal Recurrence in Medullary Thyroid Cancer: Evaluating the Role of Contralateral Prophylactic Central Neck Dissection
  • Protocol-Based Early Intensive Lipid Management Significantly Enhances LDL-C Target Achievement Post-Acute Coronary Syndrome: Insights from the BRIDGE Trial
  • Optimizing Monitoring in Head and Neck Squamous Cell Carcinoma: Tissue-Informed ctDNA Assay Shows High Accuracy and Feasibility
  • Evaluating Voice Disorder Risks in Peri- and Post-Menopausal Women Using Hormone Replacement Therapy: Insights from a Large TriNetX Cohort
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis prostate cancer public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top